References
  1. Robertson N. Enumerating neurology. Brain. 2000 Apr;123 ( Pt 4):663-4. doi: 10.1093/brain/123.4.663. PMID: 10733997.
  2. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843-2854. doi:10.1172/JCI29894
  3. Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016;5:F1000 Faculty Rev-1513. Published 2016 Jun 27. doi:10.12688/f1000research.8206.1
  4. Fichtner ML, Jiang R, Bourke A, Nowak RJ, O’Connor KC. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Front Immunol. 2020;11:776. Published 2020 May 27. doi:10.3389/fimmu.2020.00776
  5. Sasi S, Yassin MA, Fadul AM. A Case of Acquired von Willebrand Disease Secondary to Myeloproliferative Neoplasm. Case Rep Oncol. 2020;13(2):733-737. Published 2020 Jun 26. doi:10.1159/000507883
  6. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. Published 2018 Feb 9. doi:10.1038/s41408-018-0054-y
  7. Yassin MA, Nehmeh SA, Nashwan AJ, et al. A study of 18F-FLT positron emission tomography/computed tomography imaging in cases of prefibrotic/early primary myelofibrosis and essential thrombocythemia. Medicine (Baltimore). 2020;99(45):e23088. doi:10.1097/MD.0000000000023088
  8. Yassin MA, Taher A, Mathews V, Hou HA, Shamsi T, Tuğlular TF, Xiao Z, Kim SJ, Depei W, Li J, Rippin G, Sadek I, Siddiqui A, Wong RS. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria. Cancer Med. 2020 Jul;9(13):4512-4526. doi: 10.1002/cam4.3004. Epub 2020 Apr 30. PMID: 32351024; PMCID: PMC7333830.
  9. Turkina A, Wang J, Mathews V, Saydam G, Jung CW, Al Hashmi HH, Yassin M, Le Clanche S, Miljkovic D, Slader C, Hughes TP. TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. Br J Haematol. 2020 Sep;190(6):869-876. doi: 10.1111/bjh.16599. Epub 2020 Mar 30. PMID: 32227648.
  10. Tefferi A, Pardanani A. Myeloproliferative Neoplasms: A Contemporary Review. JAMA Oncol. 2015 Apr;1(1):97-105. doi: 10.1001/jamaoncol.2015.89. PMID: 26182311.
  11. Kannoth S. Paraneoplastic neurologic syndrome: A practical approach. Ann Indian Acad Neurol. 2012;15(1):6-12. doi:10.4103/0972-2327.93267
  12. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004 Nov;56(5):715-9. doi: 10.1002/ana.20269. PMID: 15468074.
  13. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment [published correction appears in Mayo Clin Proc. 2011 Apr;86(4):364. Dosage error in article text]. Mayo Clin Proc. 2010;85(9):838-854. doi:10.4065/mcp.2010.0099
  14. Cunha DG, Campos-do-Carmo G, Marujo JM, Verardino GC. Paraneoplastic Sweet’s syndrome. An Bras Dermatol. 2018;93(4):576-578. doi:10.1590/abd1806-4841.20187353
  15. Sasi S, Yassin MA, Kamran S, Mnatsakanyan V. Association of polycythemia vera with positive JAK2V617F mutation and myasthenia gravis: A report of two cases. Clin Case Rep. 2020;00:1–4. https://doi.org/10.1002/ccr3.3574
  16. Kopp CR, Jandial A, Mishra K, Sandal R, Malhotra P. Myasthenia gravis unmasked by imatinib. Br J Haematol. 2019 Feb;184(3):321. doi: 10.1111/bjh.15557. Epub 2018 Sep 10. PMID: 30203413.
  17. Sanford D, MacDonald M, Nicolle M, Xenocostas A. Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib. Hematol Rep. 2014 Jun 19;6(2):5288. doi: 10.4081/hr.2014.5288. PMID: 25013714; PMCID: PMC4091286.
  18. Sharma N, Dua H, Rosha D. Chronic myeloid leukemia with an unusual paraneoplastic syndrome. J Assoc Physicians India. 2012;60:47-48.
  19. Kumar P, Jain P, Menon H, Purvish P. Chronic myeloid leukemia presenting as paraneoplastic ocular myasthenia gravis. Ann Oncol. 2007;18(4):804-805. doi:10.1093/annonc/mdm010
  20. Pavithran K, Panakkel C, Roy D, Thomas M. Chronic myeloid leukaemia in a man with myasthenia gravis treated by thymectomy. Eur J Haematol. 2002;69(2):105-107. doi:10.1034/j.1600-0609.2002.02726.x
  21. Altomare G, Capella GL, Frigerio E. Sweet’s syndrome in a patient with idiopathic myelofibrosis and thymoma-myasthenia gravis-immunodeficiency complex: efficacy of treatment with etretinate. Haematologica. 1996 Jan-Feb;81(1):54-8. PMID: 8900854.
  22. Pérez A, Perella M, Pastor E, Cano M, Escudero J. Myasthenia gravis induced by alpha-interferon therapy. Am J Hematol. 1995 Aug;49(4):365-6. doi: 10.1002/ajh.2830490432. PMID: 7639296.
  23. Shimoda K, Gondo H, Harada M, Sano T, Nakamura M, Otsuka T, Okamura S, Niho Y. Myasthenia gravis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994 Jul;14(1):155-6. PMID: 7951105.
  24. Wanders J, Wattendorff AR, Endtz LJ, den Nijs JJ, Leeksma CH. Chronic myeloid leukemia in myasthenia gravis after long-term treatment with 6-mercaptopurine. Acta Med Scand. 1981;210(3):235-238. doi:10.1111/j.0954-6820.1981.tb09807.x
  25. Wohl MA, Wood JK. Chronic myeloid leukaemia and a myasthenic syndrome. Acta Haematol. 1979;62(4):214-218. doi:10.1159/000207574
  26. MEIR DJALDETTI, JACK PINKHAS, ANDRE DE VRIES, EDNA KOTT, HENRY JOSHUA, LEAH DOLLBERG; Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia Treated by Busulfan. Blood 1968; 32 (2): 336–340. doi: https://doi.org/10.1182/blood.V32.2.336.336
  27. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028. PMID: 20843246; PMCID: PMC5187954.
  28. Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, Bass AJ, Pretz J, Ahn J, Hricik T, Kilpivaara O, Wadleigh M, Busque L, Gilliland DG, Golub TR, Ebert BL, Levine RL. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014 May 29;123(22):e123-33. doi: 10.1182/blood-2014-02-554634. Epub 2014 Apr 16. PMID: 24740812; PMCID: PMC4041169.
  29. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood. 2012 Mar 22;119(12):2721-30. doi: 10.1182/blood-2011-11-395228. Epub 2012 Jan 25. PMID: 22279053.
  30. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 Jan 8;350(2):114-24. doi: 10.1056/NEJMoa035572. PMID: 14711910.
  31. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, Patrono C. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012 Apr 12;119(15):3595-603. doi: 10.1182/blood-2011-06-359224. Epub 2012 Jan 10. PMID: 22234683.
  32. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. doi: 10.1056/NEJM199504273321704. PMID: 7700286.
  33. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8. PMID: 23216616.
  34. Alvarez-Larrán A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernández-Boluda JC, Ayats R, Salvador C, Muntañola A, Bellosillo B, Vicente V, Hernández-Nieto L, Burgaleta C, Xicoy B, Besses C. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010 Aug 26;116(8):1205-10; quiz 1387. doi: 10.1182/blood-2010-01-263319. Epub 2010 May 27. PMID: 20508163.
  35. Ahmed W, Van Etten RA. Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program. 2013;2013:189-200. doi:10.1182/asheducation-2013.1.189
  36. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095. PMID: 21175313.
  37. Simonsson B, Gedde-Dahl T, Markevärn B, Remes K, Stentoft J, Almqvist A, Björeman M, Flogegård M, Koskenvesa P, Lindblom A, Malm C, Mustjoki S, Myhr-Eriksson K, Ohm L, Räsänen A, Sinisalo M, Själander A, Strömberg U, Bjerrum OW, Ehrencrona H, Gruber F, Kairisto V, Olsson K, Sandin F, Nagler A, Nielsen JL, Hjorth-Hansen H, Porkka K; Nordic CML Study Group. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011 Sep 22;118(12):3228-35. doi: 10.1182/blood-2011-02-336685. Epub 2011 Jun 17. PMID: 21685374.
  38. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006 Jun 1;107(11):4532-9. doi: 10.1182/blood-2005-07-2947. Epub 2006 Feb 9. PMID: 16469872.
  39. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med. 2006 Oct;12(10):1181-4. doi: 10.1038/nm1487. Epub 2006 Oct 1. PMID: 17013383.
Figure LegendsFig 1: Immune mechanism for production of AChR antibodies in Myasthenia Gravis (This figure is reproduced with permission from ‘frontiers in immunology’. Fichtner ML, Jiang R, Bourke A, Nowak RJ, O’Connor KC. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Front Immunol. 2020;11:776. Published 2020 May 27. doi:10.3389/fimmu.2020.00776)Fig 2: Immune mechanism for production of MuSK antibodies in Myasthenia Gravis (This figure is reproduced with permission from ‘frontiers in immunology’. Fichtner ML, Jiang R, Bourke A, Nowak RJ, O’Connor KC. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Front Immunol. 2020;11:776. Published 2020 May 27. doi:10.3389/fimmu.2020.00776)Fig 3: Flowchart showing the classification of Myeloproliferative Neoplasms based on chromosomal mutations.